Andrew Davis Joins Endologix as Chief Commercial Officer

Endologix LLC has welcomed a new member to its executive team, appointing Andrew Davis as its chief commercial officer (CCO).

Davis joins Endologix with an extensive background in commercial leadership, having most recently served as the CCO at Silk Road Medical, where he successfully spearheaded the go-to-market strategy for a therapy to treat carotid artery disease (TCAR). With expertise in revenue optimization, customer engagement, and market expansion, he is poised to play a key role in advancing the company’s strategic objectives, according to the company.

“We are thrilled to welcome Andrew Davis to our leadership team,” Endologix President/CEO Dr. John Liddicoat said. “He brings a strong track record of success and innovation in the commercial space, and we are confident that his leadership will help us accelerate our growth and strengthen our market position.”

Davis has more than 25 years of experience in the medical device field, as well as expertise in launching innovative, minimally invasive therapies that increase patient access and solve unmet clinical needs in cardiovascular diseases. Before his Silk Road Medical stint, Davis was vice president of Sales and Marketing at 3M’s Advanced Wound Therapy Group. Prior to 3M, he spent 15 years at Medtronic and held various vice president of sales positions in Cardiac and Vascular Therapies to include TAVR, Endovascular EVAR/TEVAR, Peripheral Vascular, and Spine/Biologics.

Davis earned a bachelor of science degree in political science from Florida State University.

In his new role, Davis will focus on aligning commercial operations with the company’s long-term vision, enhancing customer relationships, and driving new business opportunities.

“I am excited to join Endologix at such a pivotal moment,” Davis stated. “I look forward to working with the team here to expand our market presence, drive revenue growth, and deliver value to our customers.”

Endologix LLC is a California-headquartered, global medical device company that provides therapies for interventional vascular disease treatment. Endologix’s therapeutic portfolio includes products in various stages of development that treat diseases with clinically relevant unmet needs. Endologix’s commercial products, including the AFX 2 Endovascular AAA System, ALTO Abdominal Stent Graft System, and the DETOUR System, are designed to treat a range of vascular diseases, from abdominal aortic aneurysms to lower limb peripheral vascular disease. The company has offices and manufacturing sites in Irvine, Milpitas and Santa Rosa, Calif.